Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
12/2001
12/27/2001WO2001098301A1 Pyrazolopyridine compounds and use thereof as drugs
12/27/2001WO2001098299A1 Azaindole derivatives, process for their preparation, and their use as antitumor agents
12/27/2001WO2001098295A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them
12/27/2001WO2001098291A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
12/27/2001WO2001098290A2 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
12/27/2001WO2001098289A1 Novel non-psychotropic cannabinoids
12/27/2001WO2001098286A1 Nitrosated and nitrosylated taxanes, compositions and methods of use
12/27/2001WO2001097850A2 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
12/27/2001WO2001097811A1 Method for the treatment of overactive bladder
12/27/2001WO2001097806A1 Cox-2 inhibitors and the prevention of the side effects of radiation therapy
12/27/2001WO2001097751A2 New formulation comprising a betablocker and optionally a cholesterol-lowering agent
12/27/2001WO2001085719A9 Ortho-substituted anthranilic acid amides and their use as medicaments
12/27/2001WO2001049711A3 Nucleic acids encoding (poly)peptides having chips activity
12/27/2001WO2001035957A3 Stable salts of novel derivatives of 3,3-diphenylpropylamines
12/27/2001WO2001034614A3 Compositions and methods for double-targeting virus infections and targeting cancer cells
12/27/2001WO2001023390A3 Azepinoindole derivatives, the production and use thereof
12/27/2001WO2001021159A3 Pharmaceutical composition of nateglinide and another antidiabetcagent
12/27/2001US20010056183 Sulfonamides and derivatives thereof that modulate the activity of endothelin
12/27/2001US20010056100 Carboxylic acid or tetrazole derivatives containing carbamate groups are useful for treating the conditions associated with the urinary tract, pain, inflammation, respiratory states, edema formation of hypotensive vascular diseases
12/27/2001US20010056086 Aromatase inhibitors, estrogen receptor antagonists
12/27/2001US20010055758 Reagents and methods useful for detecting diseases of the prostate
12/27/2001US20010055582 Erythropoietin solution preparation
12/27/2001CA2414228A1 Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof
12/27/2001CA2414085A1 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
12/27/2001CA2413878A1 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
12/27/2001CA2413754A1 Canine hepatocyte growth factor
12/27/2001CA2413454A1 A g-protein coupled receptor
12/27/2001CA2413435A1 A recombinant cell line expressing gpcrx11 as a functional receptor validated by angiopeptin and useful for screening of agonists and antagonists
12/27/2001CA2412734A1 Renal regulatory elements and methods of use thereof
12/27/2001CA2412484A1 G-protein coupled receptors
12/27/2001CA2412362A1 Cox-2 inhibitors and the prevention of the side effects of radiation therapy
12/27/2001CA2412011A1 Chemically-modified antimicrobial peptides, compositions and methods of production and use
12/27/2001CA2411865A1 Azaindole derivatives, process for their preparation, and their use as antitumor agents
12/27/2001CA2411585A1 Novel non-psychotropic cannabinoids
12/27/2001CA2411236A1 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
12/27/2001CA2411100A1 New formulation comprising a betablocker and optionally a cholesterol-lowering agent
12/27/2001CA2410632A1 Nitrosated and nitrosylated taxanes, compositions and methods of use
12/27/2001CA2409778A1 Secreted proteins
12/26/2001CN1328550A Oxazole compounds as prostaglandin E2 agonists or antagonists
12/26/2001CN1328467A Buffered composition for dialysis
12/26/2001CN1328454A Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
12/26/2001CN1328451A Drugs for improving vesical excretory strength
12/26/2001CN1328417A Compositions and methods for treatment of mitochondrial diseases
12/26/2001CN1327847A Chinese medicine compound preparation for treating enuresis and preparing process thereof
12/26/2001CN1327800A Composite Chinese medicine for treating prostatitis, impotence and ejaculation praecox and its preparing process
12/26/2001CN1327793A Pyrrolo-triazine and pyrimidine compounds
12/26/2001CN1076623C Active component of cordyceps sinensis and its separating method
12/26/2001CN1076622C Chinese medicine for curing nephritis
12/26/2001CN1076604C Slow releasing agent of tuduvanine and its preparing method
12/26/2001CA2350043A1 Novel melanocortin -4 receptor sequences and screening assays to identify compounds useful in regulating animal appetite and metabolic rate
12/25/2001US6333350 Use of nitric oxide donors and/or substrates or nitric oxide inhibitors for regulating cervical dilatation and extensibility
12/25/2001CA2233753C Drug delivery system for two or more active substances
12/20/2001WO2001096565A2 Binding agents: chimeric ligand/receptor proteins
12/20/2001WO2001096547A2 Human kinases
12/20/2001WO2001096546A2 Protein phosphatases
12/20/2001WO2001096397A2 Cd154 variants and uses thereof
12/20/2001WO2001096347A1 HMG-CoA REDUCTASE INHIBITORS AND METHOD
12/20/2001WO2001096343A1 Substituted metal-phthalocyanines, their preparation and the use thereof
12/20/2001WO2001096337A1 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds
12/20/2001WO2001096330A2 Thrombin receptor antagonists
12/20/2001WO2001096309A1 Hydroxyformamidine derivatives and medicines containing the same
12/20/2001WO2001096308A1 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
12/20/2001WO2001096305A1 Serine protease inhibitors
12/20/2001WO2001096302A1 Piperidines for use as orexin receptor antagonists
12/20/2001WO2001096300A1 Growth hormone secretagogues
12/20/2001WO2001096285A1 Beta-amino acid nitrile derivatives
12/20/2001WO2001096279A1 Shortened synthesis of 3,3-diarylpropylamine derivatives
12/20/2001WO2001095939A1 Novel solid dispersion compositions
12/20/2001WO2001095893A1 Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects
12/20/2001WO2001095892A1 Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
12/20/2001WO2001095886A1 Bioavailable dosage form of isotretinoin
12/20/2001WO2001095859A2 Novel heterocyclic analogs of diphenylethylene compounds
12/20/2001WO2001095785A2 Modulation of immune response and methods based thereon
12/20/2001WO2001066550A3 Compounds for pdt
12/20/2001WO2001022969A3 Vasopressin agonist formulation and process
12/20/2001WO2001016108A3 Bicyclic androgen and progesterone receptor modulator compounds and methods
12/20/2001WO1997049394A3 Sold oral dosage forms of valsartan
12/20/2001US20010053536 cDNA clone HDPBI30 that encodes a novel human 7-transmembrane receptor
12/20/2001US20010053363 Novel amphipathic aldehydes and their uses as adjuvants and immunoeffectors
12/20/2001US20010053351 Inhibition of GSK-3 beta
12/20/2001CA2412632A1 Hmg-coa reductase inhibitors and method
12/20/2001CA2411472A1 Cd154 variants
12/20/2001CA2410610A1 Human kinases
12/20/2001CA2410171A1 Novel heterocyclic analogs of diphenylethylene compounds and uses thereof
12/20/2001CA2409315A1 Protein phosphatases
12/20/2001CA2407699A1 Use of an aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects
12/20/2001CA2382065A1 Bioavailable dosage form of isotretinoin
12/19/2001EP1164135A1 Substituted metal-phthalocyanines, their preparation and the use thereof
12/19/2001EP1163356A1 Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites
12/19/2001EP1163336A2 Vertebrate protein slit, dna sequence encoding it and uses thereof
12/19/2001EP1163332A1 48 human secreted proteins
12/19/2001EP1163267A1 47 human secreted proteins
12/19/2001EP1163243A2 Calanolides for inhibiting btk
12/19/2001EP1163242A2 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
12/19/2001EP1163238A1 Chemokine recpetor binding heterocyclic compounds
12/19/2001EP1163236A1 Aromatic heterocyclic compounds as anti-inflammatory agents
12/19/2001EP1163227A1 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them
12/19/2001EP1163226A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
12/19/2001EP1163225A1 Compounds and methods for modulation of estrogen receptors
12/19/2001EP1163221A1 Sulfonamide derivatives as 5ht7 receptor antagonists
1 ... 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 ... 562